Inari Medical initiated with a Hold at Stifel

Stifel analyst Mathew Blackman initiated coverage of Inari Medical with a Hold rating and $50 price target. The firm sees multiple, positive endmarket catalysts ahead, which should drive Mechanical Thrombectomy penetration higher. However, while the stock’s multiple “sits at relative/absolute discounts,” the firm starts shares at Hold as its survey work suggests stable-to-declining share over the next several years, which it says is “making it challenging to aggressively recommend the stock today.”